Researchers examined if venetoclax—a therapy commonly used in the treatment of acute myelogenous leukemia and chronic lymphocytic leukemia—was associated with an increased risk of opportunistic infections,...
Gynecologic oncologists currently lack risk models that can accurately predict an endometrial cancer diagnosis at the time of hysterectomy for endometrial intraepithelial neoplasia. To fill this gap,...
The study findings potentially challenge the conventional wisdom that the risk of Richter transformation would increase as patients with chronic lymphocytic leukemia live longer with novel treatments. This...
Researchers developed a retrospective cohort study to examine the reoperation rates and health care costs associated with reoperation for patients who underwent breast-conserving surgery.
The FDA approved irinotecan liposome with oxaliplatin, fluorouracil, and leucovorin as a first-line regimen for the management of patients with metastatic pancreatic adenocarcinoma.
Researchers assessed the efficacy of venetoclax-based treatments for patients with relapsed/refractory chronic lymphocytic leukemia. This study was presented at the 65th ASH Annual Meeting & Exposition...
In a population-based, cross-sectional study, researchers examined US women aged 20 to 49 years who were diagnosed with primary invasive breast cancer from 2000 through 2019.
Using data from observational and clinical trials, researchers examined the association between advancements in metastatic breast cancer treatment and the observed improvement in breast cancer mortality...
Researchers set out to compare the time until the next treatment in patients with chronic lymphocytic leukemia who are treated with single-agent ibrutinib at a sustained dose of 420 mg/day vs patients who...
